Pangenotypic regimens and the next generation hepatitis C virus therapy
Nancy S. Reau – 29 June 2017
Transplantation for acute alcoholic hepatitis
Patrizia Burra, Giacomo Germani – 29 June 2017
Palliative care access for hospitalized patients with end‐stage liver disease across the United States
Barret Rush, Keith R. Walley, Leo A. Celi, Neil Rajoriya, Mayur Brahmania – 29 June 2017 – Patients with end‐stage liver disease (ESLD) often have a high symptom burden. Historically, palliative care (PC) services have been underused in this population. We investigated the use of PC services in patients with ESLD hospitalized across the United States. We used the Nationwide Inpatient Sample to conduct a retrospective nationwide cohort analysis. All patients >18 years of age admitted with ESLD, defined as those with at least two liver decompensation events, were included in the analysis.
Antifibrotic therapies in liver disease: Ready for primetime?
David A. Rudnick – 29 June 2017
Developing clinical research in a clinical hepatology practice
Oren K. Fix, Terri Spinelli, Kris V. Kowdley – 29 June 2017
Contrasting the academic and nonacademic hepatology practice settings
Alexander T. Lalos, Coleman I. Smith – 29 June 2017
Idiosyncratic drug‐induced liver injury: A short review
Yo‐ichi Yamashita, Katsunori Imai, Kosuke Mima, Shigeki Nakagawa, Daisuke Hashimoto, Akira Chikamoto, Hideo Baba – 28 June 2017 – Idiosyncratic drug‐induced liver injury (iDILI) is a rare adverse drug reaction that occasionally leads to acute liver failure or even death. An aging population that uses more drugs, a constant influx of newly developed drugs, and a growing risk from herbal and dietary supplements of uncertain quality can lead to an increase in iDILI.
Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study
Harrys A. Torres, Jeff Hosry, Parag Mahale, Minas P. Economides, Ying Jiang, Anna S. Lok – 27 June 2017 – Hepatitis C virus (HCV) reactivation in patients receiving cancer treatment has been reported in retrospective studies. We sought to determine prospectively the incidence, predictors, and clinical significance of HCV reactivation during cancer treatment. HCV‐infected patients receiving cancer treatment at our institution between November 2012 and July 2016 were studied.